Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BMS acquired MyoKardia for $13.1B for cardiovascular drug mavacamten.
FDA reduced echo monitoring to every 6 months for eligible stable patients and removed key contraindications.
Bristol Myers Squibb announced plans to purchase MyoKardia for $13.1 billion in an all-cash transaction, acquiring mavacamten for hypertrophic cardiomyopathy…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS acquired MyoKardia in November 2020 for $13.1 billion (all-cash, $225/share) to obtain mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy. The thesis on a pre-revenue cardiovascular asset has been validated: launched as Camzyos after FDA approval in April 2022, the drug crossed blockbuster status with full-year 2025 revenue above $1 billion (Q4 2025 $353M, +77% YoY). An April 2025 FDA label simplification cut echo-monitoring burden and removed key contraindications, broadening the eligible population. The upside is now capped on two fronts: a 2025 Phase III failure in non-obstructive HCM removed a major expansion indication, and Cytokinetics' rival cardiac myosin inhibitor aficamten (Myqorzo) won FDA approval in December 2025, introducing the first direct class competitor in obstructive HCM.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / MyoKardia Inc. (this deal) | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. | 2022 | $4.1B | 70 |
← Browse all deals · How we score deals
More: 2020 deals · Bristol-Myers Squibb Company deals · Cardiovascular deals